Posted by Michael Wonder on 15 Jan 2024
Durvalumab with cisplatin and gemcitabine hydrochloride for the treatment of patients with unresectable or advanced biliary tract cancer
10 January 2024 - NICE has published evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with cisplatin and gemcitabine hydrochloride for the treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.
Durvalumab, when used in combination with cisplatin and gemcitabine hydrochloride, is recommended as an option for the treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer. It is only recommended if AstraZeneca provides durvalumab according to the commercial arrangement.
